Podcasts, YouTube Channels, Blogs and Related
January 23, 2023 | One Comment

In some of the comments after the last post, POGO mentioned that Josef Witt-Doerring has done two interviews with me so far and posted them on his site. The Risks of Antidepressants  and Antidepressants and Mass Shootings/Murder Suicide: An interview has also appeared on Demystifying Science podcast with  Anastasia & Michael Shilo The Podcast called […]

Read more ....

Clinical Trial Fraud
June 28, 2021 | 13 Comments

This is part two of Johanna Ryan’s posts on Ghosts in the Clinical Trial Machine or Clinical Trial Fraud.  Last weeks post reported on how doctors in three states have been convicted of handing in fake clinical-trial results from fake patients.  This week we’ll examine how small-time crooks like these ended up doing world-class medical […]

Read more ....

Ghosts in the Clinical Trial Machine
June 21, 2021 | 18 Comments

This is the first part of a two part series on clinical trial fraud from Johanna Ryan, with part 2 next week.  Jo is RxISK’s clinical trial and shoddy clinical practice sleuth – see The Maintenance Man.   Recently the U.S. Department of Justice called attention to a small but worrisome crime wave.  Health care fraud […]

Read more ....

Antidepressants: Education and Disability Certificates
March 22, 2021 | 38 Comments

This post covers difficulties primarily on antidepressants that medicines can cause to people in schools or universities who end up unable to study or do course-work, as well as the difficulties people can have trying to get off medicines, a process that can be pretty disabling. The materials linked to this post are being put […]

Read more ....

Covid and the Market in Research
April 13, 2020 | 20 Comments

  There are 3 bits to this post – an interview with Joan-Ramon Laporte.  An article by Ariane Denoyel and a Q and A with Laporte and Healy. Laporte Interview As part of a series for ROAR Magazine, Frank Barat has run some striking interviews about aspects of the Covid pandemic not usually mentioned. Here […]

Read more ....

RxISK Map: Relationship Based Medicine
November 14, 2017 | 15 Comments

Editorial Note: This is the third in a RxISK Map series of posts – See Reformation Day and Here We Stand. These link closely to the RxISK Prize. There are two aspects to finding a cure for an adverse event. One is understanding the biology. The other is getting it established that the effect happens. […]

Read more ....

Antipsychotic
Back in Olanzapine Waters
August 7, 2014 | 18 Comments

Editorial Note: Courtesy of Fast Forward, here is a 12 month follow up to Olanzapine Withdrawal: Sally’s Story; some good, some OK and some awful. Sounds and speech Twelve months later, I continue to have problems with my hearing. The serious sensitivity to sounds has settled a bit – so I don’t jump out of my […]

Read more ....

Antipsychotic
Olanzapine Withdrawal: Sally’s Story
August 5, 2014 | 239 Comments

Editorial Note: How long does withdrawal last? How much overlap is there between antipsychotic, benzodiazepine and antidepressant withdrawal? This is the first of two posts covering these issues. All answers later this week in part two. For Antipsychotic Withdrawal – see also Carole’s Story. I was prescribed olanzapine 20 mg in 2001, as a mood […]

Read more ....

Blood Sugar Pills
Great White Lies
June 27, 2013 | 3 Comments

Editorial note: this post is by Dee Mangin …. just when you were looking at pancreatic cancer on Januvia and Byetta. Sugar sugar: Less is not more Most people with diabetes now have type 2 diabetes. But for most people the high blood sugar called type 2 diabetes is not a disease. It is a […]

Read more ....

Blood Sugar Meds
Swimming with Great Whites? If you’ve got “Diabetes” look away now.
June 20, 2013 | 4 Comments

After its launch in the late 1950s, Upjohn’s Orinase (tolbutamide) became the first blockbuster hypoglycemic (blood sugar lowering) drug. Its success was born of failure. It wasn’t a replacement for insulin. Even if used early, it didn’t stop people from becoming insulin dependent. But attempts to create an early use market led to a focus on […]

Read more ....